UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications

The journal of clinical psychiatry, 2011-04, Vol.72 (4), p.464

2011

Link zum Volltext

Verfügbarkeit prüfen

Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration

The journal of clinical psychiatry, 2014-03, Vol.75 (3), p.205

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

Journal of clinical pharmacology, 2022-01, Vol.62 (1), p.55-65

2022

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration

The journal of clinical psychiatry, 2012-06, Vol.73 (6), p.856

2012

Link zum Volltext

Verfügbarkeit prüfen

What's next after 50 years of psychiatric drug development: an FDA perspective

The journal of clinical psychiatry, 2010-09, Vol.71 (9), p.1196

Laughren, Thomas P

2010

Link zum Volltext

Verfügbarkeit prüfen

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations

The journal of clinical psychiatry, 2012-09, Vol.73 (9), p.1187

2012

Link zum Volltext

Verfügbarkeit prüfen

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant

The journal of clinical psychiatry, 2011-09, Vol.72 (9), p.1166

2011

Link zum Volltext

Verfügbarkeit prüfen

Suicide rates in short-term randomized controlled trials of newer antidepressants

Journal of clinical psychopharmacology, 2006-04, Vol.26 (2), p.203-207

2006

Link zum Volltext

Verfügbarkeit prüfen

Development of a placebo effect model combined with a dropout model for bipolar disorder

Journal of pharmacokinetics and pharmacodynamics, 2013-06, Vol.40 (3), p.359-368

2013

Link zum Volltext

Verfügbarkeit prüfen

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials

Innovations in clinical neuroscience, 2013-05, Vol.10 (5-6 Suppl A), p.4S-19S

2013

Link zum Volltext

Verfügbarkeit prüfen

Female reproductive life cycle and hormones: methodology to improve clinical trials

The journal of clinical psychiatry, 2013-10, Vol.74 (10), p.1018

2013

Link zum Volltext

Verfügbarkeit prüfen

An Integrated Approach for Establishing Dosing Recommendations: Paliperidone for the Treatment of Adolescent Schizophrenia

Journal of clinical psychopharmacology, 2013-04, Vol.33 (2), p.152-156

2013

Link zum Volltext

Verfügbarkeit prüfen

Trial design issues and treatment effect modeling in multi-regional schizophrenia trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2010-07, Vol.9 (3), p.217-229

2010

Link zum Volltext

Verfügbarkeit prüfen

Commentary on “Regulatory issues in drug development programs targeting cognitive impairment in schizophrenia”

European neuropsychopharmacology, 2013-08, Vol.23 (8), p.784-785

Laughren, Thomas

2013

Link zum Volltext

Verfügbarkeit prüfen

Comorbid mood disorders and medical illness: a Food and Drug Administration perspective

Biological psychiatry (1969), 2003-08, Vol.54 (3), p.195-199

Laughren, Thomas P

2003

Link zum Volltext

Verfügbarkeit prüfen

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

Obesity (Silver Spring, Md.), 2022-11, Vol.30, p.245-245

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Perspective on the DSM-5 Approach to Classification of “Cognitive” Disorders

The journal of neuropsychiatry and clinical neurosciences, 2011, Vol.23 (2), p.126-131

Laughren, Thomas

2011

Link zum Volltext

Verfügbarkeit prüfen

Mitigating the Effects of Nonadherence in Clinical Trials

Journal of clinical pharmacology, 2016-09, Vol.56 (9), p.1151-1164

2016

Link zum Volltext

Verfügbarkeit prüfen

FDA Perspective on the DSM-5 approach to classification of "cognitive" disorders

The journal of neuropsychiatry and clinical neurosciences, 2011-01, Vol.23 (2), p.126-131

Laughren, Thomas

2011

Link zum Volltext

Verfügbarkeit prüfen

Why Are Innovative Drugs Failing in Phase III?

The American journal of psychiatry, 2017-09, Vol.174 (9), p.829-831

2017

Link zum Volltext

Verfügbarkeit prüfen

Developing novel treatments for mood disorders: accelerating discovery

Biological Psychiatry, 2002-09, Vol.52 (6), p.589-609

2002

Link zum Volltext

Verfügbarkeit prüfen

Food and Drug Administration commentary on methodological issues in negative symptom trials

Schizophrenia bulletin, 2011-03, Vol.37 (2), p.255-256

2011

Link zum Volltext

Verfügbarkeit prüfen

The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?

Schizophrenia bulletin, 2011-11, Vol.37 (6), p.1209-1217

2011

Link zum Volltext

Verfügbarkeit prüfen

The Importance of Adequately Powered Clinical Studies: Response to Khan et al

The American journal of psychiatry, 2018-02, Vol.175 (2), p.188-189

2018

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Community Functioning in People With Schizophrenia and Other Severe Mental Illnesses: A White Paper Based on an NIMH-Sponsored Workshop

Schizophrenia bulletin, 2007-05, Vol.33 (3), p.805-822

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(44)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Psychiatry
(32)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Psychology. Psychoanalysis. Psychiatry
(18)
Psychopathology. Psychiatry
(18)
United States
(18)
Antipsychotic Agents - Therapeutic Use
(13)
Psychology
(12)
Social Sciences
(12)
Adult
(11)
Adult And Adolescent Clinical Studies
(11)
Male
(11)
Pharmacology & Pharmacy
(11)
Schizophrenia
(11)
Schizophrenia - Drug Therapy
(11)
Female
(10)
United States Food And Drug Administration
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications

Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration

What's next after 50 years of psychiatric drug development: an FDA perspective

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant

Suicide rates in short-term randomized controlled trials of newer antidepressants

Development of a placebo effect model combined with a dropout model for bipolar disorder

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials

Female reproductive life cycle and hormones: methodology to improve clinical trials

An Integrated Approach for Establishing Dosing Recommendations: Paliperidone for the Treatment of Adolescent Schizophrenia

Trial design issues and treatment effect modeling in multi-regional schizophrenia trials

Commentary on “Regulatory issues in drug development programs targeting cognitive impairment in schizophrenia”

Comorbid mood disorders and medical illness: a Food and Drug Administration perspective

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment

FDA Perspective on the DSM-5 Approach to Classification of “Cognitive” Disorders

Mitigating the Effects of Nonadherence in Clinical Trials

FDA Perspective on the DSM-5 approach to classification of "cognitive" disorders

Why Are Innovative Drugs Failing in Phase III?

Developing novel treatments for mood disorders: accelerating discovery

Food and Drug Administration commentary on methodological issues in negative symptom trials

The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?

The Importance of Adequately Powered Clinical Studies: Response to Khan et al

Assessment of Community Functioning in People With Schizophrenia and Other Severe Mental Illnesses: A White Paper Based on an NIMH-Sponsored Workshop

Suchergebnisse filtern